Adverse effects of systemic advanced melanoma therapies—do BRAF/MEK inhibitors increase the incidence of mesenteric panniculitis? - Top-Institutions - MDSpire

Adverse effects of systemic advanced melanoma therapies—do BRAF/MEK inhibitors increase the incidence of mesenteric panniculitis?

  • By

  • Marcel Alexander Drews

  • Alexander Baumgarten

  • Sebastian Zensen

  • Marcel Opitz

  • Denise Bos

  • Lisa Zimmer

  • Selma Ugurel

  • Johannes Haubold

  • Dirk Schadendorf

  • Elisabeth Livingstone

  • Benedikt M. Schaarschmidt

  • May 1, 2025

  • 0 min

Share

Top Institutions in Radiology

Brief introduction explaining scope and methodology.

  • #1

    Memorial Sloan Kettering Cancer Center
    Memorial Sloan Kettering Cancer Center

    New York, NY

    Key Differentiators

    • Medical Oncology
    • Dermatology
    • Immunotherapy
    • Translational Research

  • #2

    Dana-Farber Cancer Institute
    Dana-Farber Cancer Institute

    Boston, MA

    Key Differentiators

    • Medical Oncology
    • Cancer Genomics
    • Immunotherapy

  • #3

    MD Anderson Cancer Center
    MD Anderson Cancer Center

    Houston, TX

    Key Differentiators

    • Medical Oncology
    • Dermatology
    • Immunotherapy
    • Clinical Trials

  • #4

    University of California, San Francisco (UCSF) Medical Center
    University of California, San Francisco (UCSF) Medical Center

    San Francisco, CA

    Key Differentiators

    • Medical Oncology
    • Dermatology
    • Immunotherapy
    • Radiology

  • #5

    University Hospital Essen, University of Duisburg-Essen
    University Hospital Essen, University of Duisburg-Essen

    Essen, NRW

    Key Differentiators

    • Dermatology
    • Oncology
    • Immunotherapy
    • Clinical Research

Original Source(s)

Adverse effects of systemic advanced melanoma therapies—do BRAF/MEK inhibitors increase the incidence of mesenteric panniculitis?

  • by Marcel Alexander Drews, Alexander Baumgarten, Sebastian Zensen, Marcel Opitz, Denise Bos, Lisa Zimmer, Selma Ugurel, Johannes Haubold, Dirk Schadendorf, Elisabeth Livingstone, Benedikt M. Schaarschmidt

  • May 1, 2025

Related Content

Hyperprogression of brain metastases following initiation of immune checkpoint inhibitors

AI Scribes: Efficiency for Whom?

Unresolved safety, privacy, and regulatory concerns may limit benefits of AI scribes for physicians and patients.

Mandatory Training Modules Deserve a Harder Look

A JAMA Viewpoint argues that 4 million physician-hours spent on compliance modules each year warrants institutional reassessment.